La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Zhejiang Wolwo Bio-Pharmaceutical Résultats passés
Passé contrôle des critères 2/6
Zhejiang Wolwo Bio-Pharmaceutical has been growing earnings at an average annual rate of 4.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 10.4% per year. Zhejiang Wolwo Bio-Pharmaceutical's return on equity is 12.7%, and it has net margins of 36%.
Informations clés
4.7%
Taux de croissance des bénéfices
4.7%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 10.4% |
| Rendement des fonds propres | 12.7% |
| Marge nette | 36.0% |
| Prochaine mise à jour des résultats | 23 Aug 2024 |
Mises à jour récentes des performances passées
Recent updates
Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185
Jun 30
Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking
May 27Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)
May 07Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?
Mar 22Ventilation des recettes et des dépenses
Comment Zhejiang Wolwo Bio-Pharmaceutical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 881 | 317 | 401 | 118 |
| 31 Dec 23 | 848 | 310 | 384 | 112 |
| 30 Sep 23 | 870 | 292 | 380 | 108 |
| 30 Jun 23 | 893 | 316 | 378 | 107 |
| 31 Mar 23 | 882 | 328 | 365 | 104 |
| 01 Jan 23 | 896 | 349 | 361 | 106 |
| 30 Sep 22 | 888 | 391 | 357 | 103 |
| 30 Jun 22 | 849 | 372 | 339 | 100 |
| 31 Mar 22 | 841 | 359 | 341 | 95 |
| 31 Dec 21 | 808 | 338 | 336 | 88 |
| 30 Sep 21 | 765 | 324 | 320 | 78 |
| 30 Jun 21 | 724 | 319 | 303 | 75 |
| 31 Mar 21 | 691 | 308 | 283 | 70 |
| 31 Dec 20 | 636 | 278 | 263 | 61 |
| 30 Sep 20 | 630 | 281 | 257 | 56 |
| 30 Jun 20 | 624 | 275 | 257 | 48 |
| 31 Mar 20 | 612 | 274 | 257 | 42 |
| 31 Dec 19 | 639 | 298 | 259 | 37 |
| 30 Sep 19 | 615 | 290 | 256 | 29 |
| 30 Jun 19 | 556 | 259 | 235 | 19 |
| 31 Mar 19 | 532 | 247 | 222 | 16 |
| 31 Dec 18 | 501 | 233 | 205 | 12 |
| 30 Sep 18 | 478 | 227 | 188 | 10 |
| 30 Jun 18 | 439 | 211 | 171 | 11 |
| 31 Mar 18 | 411 | 200 | 163 | 9 |
| 31 Dec 17 | 386 | 186 | 158 | 6 |
| 30 Sep 17 | 367 | 175 | 156 | 5 |
| 30 Jun 17 | 344 | 154 | 157 | 0 |
| 31 Mar 17 | 324 | 139 | 153 | 0 |
| 31 Dec 16 | 312 | 129 | 151 | 0 |
| 30 Sep 16 | 303 | 129 | 141 | 0 |
| 30 Jun 16 | 283 | 121 | 136 | 0 |
| 31 Mar 16 | 277 | 122 | 130 | 0 |
| 31 Dec 15 | 267 | 118 | 126 | 0 |
| 30 Sep 15 | 261 | 116 | 121 | 0 |
| 30 Jun 15 | 252 | 112 | 118 | 0 |
| 31 Mar 15 | 247 | 110 | 116 | 0 |
| 31 Dec 14 | 240 | 100 | 122 | 0 |
| 30 Sep 14 | 228 | 90 | 121 | 0 |
| 30 Jun 14 | 211 | 78 | 116 | 0 |
| 31 Mar 14 | 202 | 68 | 114 | 0 |
| 31 Dec 13 | 194 | 71 | 102 | 0 |
Des revenus de qualité: 300357 has high quality earnings.
Augmentation de la marge bénéficiaire: 300357's current net profit margins (36%) are lower than last year (37.2%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 300357's earnings have grown by 4.7% per year over the past 5 years.
Accélération de la croissance: 300357's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 300357 had negative earnings growth (-3.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendement des fonds propres
ROE élevé: 300357's Return on Equity (12.7%) is considered low.